Abstract 6606: Biomarker discovery in non-small-cell lung cancer enabled by deep multi-omics profiling of proteins, metabolites, transcripts, and genes in blood
Authors: Choi Jinlyung , Kokate Ajinkya , Khaledian Ehdieh , Liu Manway , Prasad Preethi , Blume John , Chan Jessica , Cuaresma Rea , Dai Kevin , Khadka Manoj , Khin Thidar , Kodama Yuya , Lee Joon-Yong , Malekpour Hoda , Mora Megan , Mudaliar Nithya , Golmaei Sara Nouri , Ramaiah Madhuvanthi , Ramaswamy Saividya , Spiro Peter , Vitko Dijana , Swaminathan Kavya , Yee James , Young Brian , Belthangady Chinmay , Wilcox Bruce , Koh Brian , Ma Philip 
Published: April 2023

Lung cancer is the leading cause of cancer-related deaths in the United States, with estimates of 236,740 new cases and 118,830 deaths in 2022 secondary to the disease. Blood-based liquid biopsies hold promise to reduce morbidity and mortality from lung cancer by enabling early detection to downstage disease at diagnosis, theragnostic identification of patients most likely to be helped or harmed by therapy, monitoring of therapeutic efficacy, and detection of residual disease. PrognomiQ’s multi-omics platform comprehensively profiles proteins, metabolites, lipids, mRNA, and cfDNA in blood samples which can be used for the development of liquid biopsy tests with high sensitivity and specificity for lung cancer. We conducted a case-control study comprising 1031 subjects: 361 subjects with untreated non-small-cell lung cancer (NSCLC) and 670 matched controls which included 340 subjects with salient pulmonary and gastrointestinal co-morbidities. Blood samples from each subject were processed to provide 7 different `omics readouts. LCMS was used to detect and quantify proteins, metabolites, and lipids. In addition, cfDNA and mRNA were assayed using next-generation sequencing. cfDNA reads were analyzed to estimate fragment-lengths, copy-number variation, and CpG site methylation. All molecular data were normalized using standard methods specific to each assay. Univariate analyses of cases vs controls were performed to identify differentially abundant features on all available samples per assay. We detected 9,868 proteins, 605 lipids, 329 metabolites, and 109,070 mRNA transcripts. Of these, 3,098 proteins, 210 lipids, 57 metabolites, and 30,236 mRNA transcripts were significantly different (FWER &lt; 0.05) in cases versus controls. Gene set enrichment analysis on statistically significant transcripts and proteins identified multiple gene-ontology terms associated with cancer including the Wnt signaling process and IgA immunoglobulin complex, respectively. From cfDNA data, we identified 234 non-contiguous genomic regions associated with the fragment-length disorder, 4,790 with copy-number variation, and 74 differentially methylated genomic regions spanning 184 CpG sites (FWER &lt; 0.05). With the premise that deviations from copy number neutrality are more likely to indicate a tumor contribution, we then focused our examination on those differentially expressed proteins that overlap with differentially expressed mRNA transcripts as well as CNV genomic regions. We identified 52 protein coding genes including E-cadherin (associated with EMT) and related binding proteins such as RAB11B, CAPZB, EPS15, FLNB, MYH9, STK24 and YWHAE. Ongoing machine-learning-based classifier training to distinguish between cancer and non-cancer can serve as the basis for the development of high-sensitivity liquid-biopsy tests for lung cancer.

Citation Format: Jinlyung Choi, Ajinkya Kokate, Ehdieh Khaledian, Manway Liu, Preethi Prasad, John Blume, Jessica Chan, Rea Cuaresma, Kevin Dai, Manoj Khadka, Thidar Khin, Yuya Kodama, Joon-Yong Lee, Hoda Malekpour, Megan Mora, Nithya Mudaliar, Sara Nouri Golmaei, Madhuvanthi Ramaiah, Saividya Ramaswamy, Peter Spiro, Dijana Vitko, Kavya Swaminathan, James Yee, Brian Young, Chinmay Belthangady, Bruce Wilcox, Brian Koh, Philip Ma. Biomarker discovery in non-small-cell lung cancer enabled by deep multi-omics profiling of proteins, metabolites, transcripts, and genes in blood. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6606.